1-855-378-42281-855-378-4228
One of the outpatient rehab options for individuals in Wixon Valley who are battling with opioid abuse and addiction is opioid maintenance therapy. Some facilities and doctors are authorized to give specific medications to opioid addicted clients, many that are opioids themselves and are addiction. With low enough doses however, the user does not experience being high but also does not experience intense cravings and isn't experiencing opioid withdrawal. Methadone is the first drug administered for this reason, but there are other options to choose from.
Methadone is an opioid and can be taken at an out-patient medical center licensed to dispense the drug, which is taken daily as a pill or liquid. The cost of the med is around one hundred and fifty dolloars a month. Buprenorphine is also an opioid based med, and is in pill form often taken every other day. But unlike Methadone which can only be dispensed in structured clinics, Buprenorphine can be and is prescribed and dispensed in doctor's offices. The cost monthly of buprenorphine is around three hundred dollars per month for the generic version of the medication. There is also a version of buprenorphine containing the drug naloxone, which is a med which blocks the effects of opioids. An individual consuming this version of the drug, also known as Suboxone, would find it more difficult to feel high from opioids if they relapsed while taking the drug. It is also taken every day, and is priced about $450 per month. Naltrexone is an additional medication used in opioid maintenance therapy, but unlike the other drugs mentioned here it is an opiate blocker and isn't an opiate. A person has the choice to take this medication as a monthly injection, which is called Vivitrol. As an opioid blocker, the drug prevents a person from getting high from opioids, and therefore lowers the risk associated with relapse. This daily shot costs anywhere from $1000 to $1200 monthly.
For All Drug and Alcohol Treatment Facilities In Wixon Valley, Click Here.
